Mol. Cells 2011; 31(1): 9-15
Published online December 24, 2011
https://doi.org/10.1007/s10059-011-0008-8
© The Korean Society for Molecular and Cellular Biology
Correspondence to : *Correspondence: hg-kim@korea.ac.kr (HK); cyjcow@snu.ac.kr (YC)
Telomerase reverse transcriptase (TERT), the catalytic subunit of the enzyme telomerase, is robustly expressed in cancer cells. TERT enables cells to avoid chromosome shortening during repeated replication by maintaining telomere length. However, several lines of evidence indi-cate that many cancer cells exhibit shorter telomere length than normal tissues, implying an additional function of TERT in tumor formation and progression. Here, we report a telomerase activity-independent function of TERT that induces cancer stemness in glioma cells. Overexpression of TERT712, a telomerase activity-deficient form of TERT, in U87MG cells promoted cell self-renewal in vitro, and induced EGFR expression and formation of gliomas exhibiting cellular heterogeneity in vivo. In patients with gliobla-stoma multiforme, TERT expression showed a high corre-lation with EGFR expression, which is closely linked to the stemness gene signature. Induction of differentiation and TERT-knockdown in glioma stem cells led to a marked reduction in EGFR expression, cancer stemness, and anti-cancer drug resistance. Together, our findings indicate that TERT plays a crucial role in tumor progres-sion by promoting cancer stemness through expression of EGFR.
Keywords bFGF, EGFR, glioblastoma multiforme, glioma stem cells, telomerase
Mol. Cells 2011; 31(1): 9-15
Published online January 31, 2011 https://doi.org/10.1007/s10059-011-0008-8
Copyright © The Korean Society for Molecular and Cellular Biology.
Samuel Beck1,5, Xun Jin2,5, Young-Woo Sohn2, Jun-Kyum Kim2, Sung-Hak Kim2, Jinlong Yin1, Xumin Pian2, Sung-Chan Kim3, Do-Hyun Nam4, Yun-Jaie Choi1,*, and Hyunggee Kim2,*
1National Research Laboratory of Animal Cell Biotechnology, School of Agricultural Biotechnology, Seoul National University, Seoul 152-742, Korea, 2Cell Growth Regulation Laboratory (CGRL), School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Korea, 3Department of Biochemistry, College of Medicine, Hallym University, Chuncheon 200-702, Korea, 4Department of Neurosurgery, Samsung Medical Center and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea, 5These authors contributed equally to this work.
Correspondence to:*Correspondence: hg-kim@korea.ac.kr (HK); cyjcow@snu.ac.kr (YC)
Telomerase reverse transcriptase (TERT), the catalytic subunit of the enzyme telomerase, is robustly expressed in cancer cells. TERT enables cells to avoid chromosome shortening during repeated replication by maintaining telomere length. However, several lines of evidence indi-cate that many cancer cells exhibit shorter telomere length than normal tissues, implying an additional function of TERT in tumor formation and progression. Here, we report a telomerase activity-independent function of TERT that induces cancer stemness in glioma cells. Overexpression of TERT712, a telomerase activity-deficient form of TERT, in U87MG cells promoted cell self-renewal in vitro, and induced EGFR expression and formation of gliomas exhibiting cellular heterogeneity in vivo. In patients with gliobla-stoma multiforme, TERT expression showed a high corre-lation with EGFR expression, which is closely linked to the stemness gene signature. Induction of differentiation and TERT-knockdown in glioma stem cells led to a marked reduction in EGFR expression, cancer stemness, and anti-cancer drug resistance. Together, our findings indicate that TERT plays a crucial role in tumor progres-sion by promoting cancer stemness through expression of EGFR.
Keywords: bFGF, EGFR, glioblastoma multiforme, glioma stem cells, telomerase
Nensi Shrestha, Hridaya Shrestha, Taeyong Ryu, Hangun Kim, Shishli Simkhada, Young-Chang Cho, So-Yeon Park, Sayeon Cho, Kwang-Youl Lee, Jae-Hyuk Lee, and Kwonseop Kim
Mol. Cells 2018; 41(4): 320-330 https://doi.org/10.14348/molcells.2018.2292Hyuna Kim, Youngmi Kim, and Dooil Jeoung
Mol. Cells 2017; 40(1): 54-65 https://doi.org/10.14348/molcells.2017.2258Hyuna Kim, Youngmi Kim, Hyeonjung Goh, and Dooil Jeoung
Mol. Cells 2016; 39(3): 229-241 https://doi.org/10.14348/molcells.2016.2244